News | Cath Lab | January 23, 2017

New Report Highlights National Trends in Heart Disease Treatments

Data show registries are advancing effectiveness and safety of patient care

NCDR, ACC, JACC, American College of Cardiology, national trends, heart disease treatments, trends in cardiovascular care

January 23, 2017 — Over 93 percent of heart attack patients are receiving stents within the guideline-recommended threshold of 90 minutes after arriving at the hospital, with the median time to stenting only 59 minutes, according to new data. The data are part of a broad report on trends in heart disease care from the American College of Cardiology’s National Cardiovascular Data Registry, published in the Journal of the American College of Cardiology.

The report “Trends in Cardiovascular Care in the United States: a Report from Four American College of Cardiology National Cardiovascular Data Registry Programs,” provides insights into the patient populations, participating centers and patterns of care based on 2014 data from four of the 10 NCDR programs — CathPCI Registry, ICD Registry, ACTION Registry-GWTG and IMPACT Registry. 

The authors of the report said the registry data provide unique perspectives into the care and outcomes of heart disease care in the United States and illustrate the strength of national quality programs, like NCDR, in advancing the effectiveness and safety of treatments for heart disease patients.

“We were able to report on the care and outcomes of patients undergoing common cardiovascular procedures, including percutaneous coronary interventions, implantable defibrillators and interventions for congenital heart disease, as well as for patients with acute heart attacks,” NCDR Management Board Chair and lead author of the study Frederick A. Masoudi, M.D., MSPH, FACC, said. “In some cases, hospitals are consistently providing excellent care; the registries, however, allow us to identify those aspects of care where the cardiovascular clinical community can improve.”

Key findings from each registry include:

CathPCI Registry

  • Of the 667,424 patients undergoing PCI in 2014, 35.3 percent of PCIs were performed for elective indications, compared to 64.7 percent performed for non-elective indications;
  • Between 2011 and 2014, the use of femoral access decline from 88.4 percent to 74.5 percent, while the use of radial access increased from 10.9 percent to 25.2 percent;
  • Use of evidence-based therapies, including aspirin, P2Y12 inhibitors and statins for eligible patients, continue to remain high at 93.3 percent;
  • Median door-to-balloon time for primary PCI for ST-elevation myocardial infarction (STEMI) also remains strong at 59 minutes for patients receiving PCI at the presenting hospital and 105 minutes for transfer patients.

ICD Registry

  • Of the 158,649 patients receiving implantable cardioverter defibrillator (ICD) therapy in 2014, 120,228 received a device for primary prevention reasons, compared to 38,421 who received a device for secondary prevention indications;
  • Of all ICD implants in 2014, 25 percent involved single chamber devices, 32 percent involved dual chamber devices and 43 percent involved cardiac resynchronization therapy-defibrillator (CRT-D) devices, compared to 19 percent, 37 percent and 44 percent, respectively, in 2011; and
  • While use of evidence-based therapies are generally high, performance on a composite medication metric, including use of ACE or ARB for patients with left ventricular systolic dysfunction (LVSD) and beta blockers for patients with LVSD, could be a target for quality improvement efforts. Between 2011 and 2014 the composite rate of use grew from 76.7 percent to 80.3 percent, with room for continued improvement.

ACTION Registry-GWTG

  • Of the 182,903 patients with acute myocardial infarction (AMI) in 2014, 71,368 had STEMI, while 111,535 had non-ST-segment elevation acute coronary syndromes (NSTEMI);
  • There is room for improvement in the areas of overall defect-free care (78.4 percent); P2Y12 inhibitor use in eligible patients (56.7 percent); and use of aldosterone antagonists in patients with LV systolic dysfunction and either diabetes or heart failure (12.8 percent);
  • Compared to NSTEMI patients, STEMI patients were more likely to experience certain adverse events during hospitalization, including death (6.4 percent vs. 3.4 percent); cardiogenic shock (4.4 percent vs. 1.6 percent), or bleeding (8.5 percent vs. 5.5 percent); and
  • Of the STEMI patients, 95.8 percent underwent coronary angiography and 90.7 percent underwent PCI, compared to NSTEMI patients of which 81.9 percent underwent coronary angiography and 52.4 percent underwent PCI.

IMPACT Registry

  • Of the 20,169 patients with congenital heart disease undergoing cardiac catheterization or a catheter-based intervention, 86 percent were under the age of 18 and 24.6 percent were under one year old;
  • Procedures such as atrial septal defect (ASD) closure, patent ductus arteriosus (PDA) closure, aortic coarctation stenting and pulmonary valvulolasty had success rates exceeding 84 percent. Aortic coarctation balloon angioplasty was less successful at 55.1 percent; and
  • Device embolization was reported in 1.2 percent of ASD closure procedures and 1.1 percent of PDA closure procedures. A clinically significant increase in aortic regurgitation follow valvuloplasty was noted in 10.6 percent of cases.

In a corresponding executive summary also published in JACC, Masoudi said, “NCDR data provide a unique, clinically rich national perspective on the care and outcomes of high-impact cardiovascular conditions and procedures that are not available elsewhere.”

The full report can be read here.

For more information: www.jacc.org

 

Related NCDR CathPCI Registry articles:

• Radial Access, Same-Day Cardiac Procedure Could Save $300 Million Annually
• Better Prognosis for Some PCI Patients When Operators Perform More Procedures
• Study Finds Significant Variability in Doctors' Angioplasty Death Rates

 

Reference:

Masoudi, F.A., Ponirakis, A., de Lemos, J.A., Jollis, J.G., et al. "Trends in U.S. Cardiovascular Care: 2016 Report from 4 ACC National Cardiovascular Data Registries," JACC. Published online Dec. 23, 2016. DOI: https://doi.org/10.1016/j.jacc.2016.12.005

Related Content

Gallery | Cath Lab | October 31, 2019
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
Overlay Init